Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Acuity Medical International, Inc.
ClinicalTrials.gov Identifier:
NCT01600300
First received: May 14, 2012
Last updated: May 15, 2012
Last verified: May 2012

May 14, 2012
May 15, 2012
August 2002
April 2004   (final data collection date for primary outcome measure)
Change in visual acuity [ Time Frame: Day 5, Day 12 ] [ Designated as safety issue: No ]
Change in visual acuity as measured with ETDRS eye chart
Same as current
Complete list of historical versions of study NCT01600300 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration
A Double-Blind, Placebo-Controlled Feasibility Study to Evaluate the Efficacy of TESMAC™ (Transcutaneous Electrical Stimulation of the Macula)

Hypothesis: external electrical stimulation of the retina with low level electrical currents improves visual acuity in subjects with age-related dry macular degeneration.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Macular Degeneration
  • Device: Tesmac
    Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
    Other Name: Theramac
  • Device: Sham Tesmac device
    Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
  • Placebo Comparator: Sham
    Treatment with inactivate Tesmac device
    Intervention: Device: Sham Tesmac device
  • Active Comparator: Tesmac
    Treatment with active Tesmac device
    Intervention: Device: Tesmac
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
April 2004
April 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosis of Macular Degeneration, i.e., at least three, hard or soft drusen must be present there must be RPE changes (migration, clumping or atrophy) within the central 6mm of the retina.
  2. As a prerequisite for entry into the study, all patients will have their diagnosis of dry AMD confirmed by an ophthalmologist via a retinal exam and Fluorescein Angiography will also determine whether or not the subject is a candidate for laser surgery. Only subjects who have AMD will be admitted to the study.
  3. Both sexes are eligible.
  4. The best-corrected visual acuity can be no better than 20/40 and no worse than 20/100 in the treated eyes.
  5. Age greater than 50.
  6. Subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent.
  7. Both eyes of the subject must show no evidence of wet AMD. If one eye is wet and the fellow eye is dry, the subject will be excluded.

Exclusion Criteria:

  1. Subjects with seizure disorders.
  2. Subjects with additional eye-related diseases that have associated ongoing retinal bleeding.
  3. Subjects with any implanted electrical device.
  4. Subjects who have smoked, on average, more than half a pack of cigarettes per day during the last 5 years.
  5. Subjects with known allergy to contrast dye.
  6. Subjects who are in poor general health, have unstable diseases, are terminally ill, have a life expectancy of less than 12 months, are non-ambulatory or bedridden, live in a geographical location which would likely prevent regular attendance at study visits or are considered not suitable for participation by the investigator.
  7. Subjects exposed to an investigational device or drug within the past 30 days or involved concurrently in other treatment clinical trials. Note: Subjects participating in studies investigating the natural progression of AMD may not participate in this trial.
  8. Subjects unwilling to adhere to visit or examination schedules as described in the study protocol.
  9. Subjects with a known history of alcoholism, drug abuse, psychosis, clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
  10. Any subject experiencing an acute stressor that, in the opinion of the investigator, might affect the course or treatment of AMD.
  11. Anyone with diagnosis of malignant or poorly controlled glaucoma in the eye(s) that would be treated.
  12. Anyone with diabetic retinopathy.
  13. Anyone with a progressive corneal dystrophy in the eye(s) that would be treated.
  14. Anyone with any noted chorio retinal disease (other than AMD) in the eye(s) that would be treated.
  15. Anyone with a progressive nuclear cataract in the eye(s) that would be treated. Stable cortical cataract patients may be included. Any patient with an immature cataract, one in which scattered opacities are separated by clear zones, may be included in the study. All patients with mature, hypermature or morgagnian cataracts in the eye(s) that would be treated will be excluded. Patients with a grade 3 or grade 4 cataract in the eye(s) that would be treated will be excluded. Grade 1 and Grade 2 cataract patients may be included in this study.
  16. Subjects participating in an AMD natural history study.
  17. Subjects with one eye diagnosed with wet AMD.
  18. Subjects with any previous retinal bleeding, injury, or retinal surgery.
  19. Subjects that have previously been diagnosed with amblyopia.
  20. Subjects currently taking blood-thinning medication.
  21. Subjects cannot have previously been involved in a TESMAC™ study.
  22. Subjects that take two or more of the following antioxidants daily at the following doses: 500 milligrams of vitamin C; 400 international units of vitamin E; 15 milligrams of beta-carotene; 80 milligrams of zinc as zinc oxide; and two milligrams of copper as cupric oxide and have done this for more than 2 years. These subjects may be included, but their study results will be analyzed separately.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01600300
TESMAC-2002.2
Not Provided
Acuity Medical International, Inc.
Acuity Medical International, Inc.
Not Provided
Principal Investigator: Richard Beauchemin, MD WNC Eye Care Associates PA
Acuity Medical International, Inc.
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP